Objective To investigate the clinical efficacy and safety of nivolumab(PD-1 inhibitor)in combination with lenvatinib and FOLFOX regimen[5-fluorouracil(5-FU),oxaliplatin(L-OHP),and calcium folinate(LV)]in the treatment of intermediate and advanced hepatocellular carcinoma(HCC)via hepatic arterial infusion chemotherapy(HAIC).Methods A total of 160 patients with intermediate and advanced HCC admitted to the Second Affiliated Hospital of Guilin Medical University from January 2021 to January 2023 were randomly divided into the control group and the observation group,with 80 patients in each group,using a random number table.The control group received once-daily oral lenvatinib and intravenous carrizumab infusions for 12 weeks as part of transcatheter arterial chemoembolization(TACE)therapy.The observation group was administered with FOLFOX regimen via HAIC chemotherapy,plus intravenous infusion of carrizumab for 12 weeks and once-daily oral lenvatinib.All the patients were followed up regularly.The clinical efficacy was evaluated using the mRECIST criteria.The objective response rate(ORR),disease control rate(DCR),overall survival(OS),progression-free survival(PFS),and incidence of adverse reactions were compared between the two groups.Results There were no significant differences in the objective response rate and incidence of adverse reactions between the groups.The disease control rate,overall survival,and progression-free survival in the observation group were significantly higher than those in the control group(P<0.05).Conclusions The FOLFOX-HAIC regimen in combination with nivolumab and lenvatinib is safe and effective for the treatment of intermediate and advanced HCC,without adverse reactions.It can prolong the overall survival and progression-free survival,and improve the patient's quality of life.

ObjectiveTo observe the clinical efficacy of Qianghuo Shengshitang combined with ozone injection and radiofrequency thermocoagulation target puncture in the treatment of cervical spondylotic radiculopathy （wind-cold blockage type）. MethodSixty-eight patients with cervical spondylotic radiculopathy who were treated in Henan Province Hospital of Traditional Chinese Medicine from August 2020 to May 2021 were included and grouped into a control group and a research group by random number table， with 34 patients in each group. The control group was administrated with placebo granules of Qianghuo Shengshitang， and treated with ozone injection and radiofrequency thermocoagulation target puncture at the same time. The research group was given modified Qianghuo Shengshitang combined with ozone injection and radiofrequency thermocoagulation target puncture. Before and after treatment， patients in two groups were tested for the levels of tumor necrosis factor-α （TNF-α）， procalcitonin （PCT）， interleukin-2 （IL-2）， interleukin-1β （IL-1β）， 6-ketoprostaglandin E1α （6-keto-PGE1α）， plasma substance P （SP）， β-endorphin （β-EP）， lipid peroxide （LPO）， malondialdehyde （MDA）， and superoxide dismutase （SOD）. The pain visual scale （VAS）， cervical dysfunction index （NDI）， and clinical evaluation scale for cervical spondylosis （CASCS） were given to patients to evaluate the clinical efficacy. ResultCompared with those before treatment， the levels of IL-1β， PCT， and TNF-α in two groups were decreased， and the level of IL-2 was increased （P<0.05）. The improvement of IL-1β， PCT， TNF-α， and IL-2 was more obvious in the research group as compared with the control group （P<0.05）. After treatment， the levels of SOD in two groups were increased， while the levels of LPO and MDA were decreased （P<0.05）. After treatment， the improvement of SOD， LPO， and MDA was more obvious in the research group as compared with the control group （P<0.05）. Compared with those before treatment， the levels of SP and 6-keto-PGE1α in two groups were decreased after treatment， and the level of β-EP was increased （P<0.05）. The improvement of -keto-PGE1α and β-EP was more obvious in the research group as compared with the control group after treatment （P<0.05）. Compared with those before treatment， the VAS and NDI scores of the research group were decreased， and the CASCS scores were increased （P<0.05）. After treatment， the improvement of VAS， NDI， and CASCS of the research group was more obvious as compared with the control group （P<0.05）. After treatment， the total effective rate of patients in the research group was higher than that in the control group （Z=2.018， P<0.05）. ConclusionModified Qianghuo Shengshitang combined with ozone injection and radiofrequency thermocoagulation target puncture in the treatment of patients with cervical spondylotic radiculopathy （wind-cold blockage type） can inhibit inflammation， remove oxygen free radicals， improve the level of pain mediators， relieve pain， and improve cervical spine function and clinical efficacy.